Astria Therapeutics, Inc. has announced that it will present new clinical data at the 2025 US Hereditary Angioedema Association National Summit. The company is set to present four posters, showcasing various aspects of its ongoing research. Timothy Craig, D.O., will provide an encore presentation on the global Phase 3 trial of navenibart in hereditary angioedema patients. Michael E. Manning, M.D., will present initial safety and efficacy data from the Phase 1b/2 and long-term open-label trials. Mindy DeMarco, RN, will address recruitment challenges in rare disease trials, while H. Henry Li, M.D., will discuss interim results on attack severity reduction from the ALPHA-STAR trial. The results will be presented during the summit, taking place from July 10-13, 2025, in Baltimore, Maryland.